Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Detection of a Novel gyrB Mutation Associated With Fluoroquinolone-Nonsusceptible Salmonella enterica serovar Typhimurium Isolated From a Bloodstream Infection in Ghana.

Al-Emran HM, Heisig A, Dekker D, Adu-Sarkodie Y, Cruz Espinoza LM, Panzner U, von Kalckreuth V, Marks F, Park SE, Sarpong N, May J, Heisig P.

Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S47-9. doi: 10.1093/cid/civ790.

PMID:
26933021
2.

The Emergence of Reduced Ciprofloxacin Susceptibility in Salmonella enterica Causing Bloodstream Infections in Rural Ghana.

Eibach D, Al-Emran HM, Dekker DM, Krumkamp R, Adu-Sarkodie Y, Cruz Espinoza LM, Ehmen C, Boahen K, Heisig P, Im J, Jaeger A, von Kalckreuth V, Pak GD, Panzner U, Park SE, Reinhardt A, Sarpong N, Schütt-Gerowitt H, Wierzba TF, Marks F, May J.

Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S32-6. doi: 10.1093/cid/civ757.

PMID:
26933017
3.

Investigation of Antifouling Properties of Surfaces Featuring Zwitterionic α-Aminophosphonic Acid Moieties.

Wagner N, Zimmermann P, Heisig P, Klitsche F, Maison W, Theato P.

Macromol Biosci. 2015 Dec;15(12):1673-8. doi: 10.1002/mabi.201500196. Epub 2015 Sep 2.

PMID:
26332285
4.

Biomimetic PEG-catecholates for stabile antifouling coatings on metal surfaces: applications on TiO2 and stainless steel.

Khalil F, Franzmann E, Ramcke J, Dakischew O, Lips KS, Reinhardt A, Heisig P, Maison W.

Colloids Surf B Biointerfaces. 2014 May 1;117:185-92. doi: 10.1016/j.colsurfb.2014.02.022. Epub 2014 Feb 20.

PMID:
24632391
5.

Uncomplicated Urinary Tract Infections and Antibiotic Resistance-Epidemiological and Mechanistic Aspects.

Wiedemann B, Heisig A, Heisig P.

Antibiotics (Basel). 2014 Jul 22;3(3):341-52. doi: 10.3390/antibiotics3030341. Review.

6.

An improved assay for the detection of alterations in bacterial DNA supercoiling in vivo.

Abu Mraheil M, Heisig A, Heisig P.

Pharmazie. 2013 Jul;68(7):541-8.

PMID:
23923635
7.

Prominence of an O75 clonal group (clonal complex 14) among non-ST131 fluoroquinolone-resistant Escherichia coli causing extraintestinal infections in humans and dogs in Australia.

Platell JL, Trott DJ, Johnson JR, Heisig P, Heisig A, Clabots CR, Johnston B, Cobbold RN.

Antimicrob Agents Chemother. 2012 Jul;56(7):3898-904. doi: 10.1128/AAC.06120-11. Epub 2012 Apr 23.

8.

EUCAST expert rules in antimicrobial susceptibility testing.

Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G.

Clin Microbiol Infect. 2013 Feb;19(2):141-60. doi: 10.1111/j.1469-0691.2011.03703.x. Epub 2011 Nov 25. Review.

9.

Commonality among fluoroquinolone-resistant sequence type ST131 extraintestinal Escherichia coli isolates from humans and companion animals in Australia.

Platell JL, Cobbold RN, Johnson JR, Heisig A, Heisig P, Clabots C, Kuskowski MA, Trott DJ.

Antimicrob Agents Chemother. 2011 Aug;55(8):3782-7. doi: 10.1128/AAC.00306-11. Epub 2011 Jun 6.

10.

Identification of variables for aerobic bacterial density at clinically relevant skin sites.

Reichel M, Heisig P, Kampf G.

J Hosp Infect. 2011 May;78(1):5-10. doi: 10.1016/j.jhin.2011.01.017.

PMID:
21439679
11.

CMY-42, a novel plasmid-mediated CMY-2 variant AmpC beta-lactamase.

Hentschke M, Kotsakis SD, Wolters M, Heisig P, Miriagou V, Aepfelbacher M.

Microb Drug Resist. 2011 Jun;17(2):165-9. doi: 10.1089/mdr.2010.0137. Epub 2011 Mar 9.

PMID:
21388298
12.

Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance.

Emrich NC, Heisig A, Stubbings W, Labischinski H, Heisig P.

J Antimicrob Chemother. 2010 Dec;65(12):2530-3. doi: 10.1093/jac/dkq375. Epub 2010 Oct 12.

PMID:
20940181
13.

Fluoroquinolone resistance mechanisms in multidrug-resistant Escherichia coli isolated from extraintestinal infections in dogs.

Gibson JS, Cobbold RN, Kyaw-Tanner MT, Heisig P, Trott DJ.

Vet Microbiol. 2010 Nov 20;146(1-2):161-6. doi: 10.1016/j.vetmic.2010.04.012. Epub 2010 Apr 21.

PMID:
20471187
14.

[Urinary tract infections and antibiotic resistance].

Heisig P.

Urologe A. 2010 May;49(5):612-7. doi: 10.1007/s00120-010-2259-y. Review. German.

PMID:
20449778
15.

Skin bacteria after chlorhexidine exposure-is there a difference in response to human beta-Defensin-3?

Reichel M, Heisig A, Heisig P, Kampf G.

Eur J Clin Microbiol Infect Dis. 2010 Jun;29(6):623-32. doi: 10.1007/s10096-010-0904-4. Epub 2010 Mar 27.

PMID:
20339890
16.

Identification of Qnr and AAC(6')-1b-cr plasmid-mediated fluoroquinolone resistance determinants in multidrug-resistant Enterobacter spp. isolated from extraintestinal infections in companion animals.

Gibson JS, Cobbold RN, Heisig P, Sidjabat HE, Kyaw-Tanner MT, Trott DJ.

Vet Microbiol. 2010 Jul 14;143(2-4):329-36. doi: 10.1016/j.vetmic.2009.11.031. Epub 2009 Dec 3.

PMID:
20036084
17.

Type II topoisomerases--inhibitors, repair mechanisms and mutations.

Heisig P.

Mutagenesis. 2009 Nov;24(6):465-9. doi: 10.1093/mutage/gep035. Epub 2009 Sep 17. Review.

PMID:
19762349
18.

Alcohols for skin antisepsis at clinically relevant skin sites.

Reichel M, Heisig P, Kohlmann T, Kampf G.

Antimicrob Agents Chemother. 2009 Nov;53(11):4778-82. doi: 10.1128/AAC.00582-09. Epub 2009 Sep 8.

19.

Pitfalls in efficacy testing--how important is the validation of neutralization of chlorhexidine digluconate?

Reichel M, Heisig P, Kampf G.

Ann Clin Microbiol Antimicrob. 2008 Dec 2;7:20. doi: 10.1186/1476-0711-7-20.

20.

The role of intra- and extragenic compensatory mutations in the suppression of fluoroquinolone resistance in a Salmonella Typhimurium gyrA mutant (D87G).

Preisler A, Heisig P.

J Antimicrob Chemother. 2009 Feb;63(2):290-4. doi: 10.1093/jac/dkn480. Epub 2008 Nov 24.

PMID:
19033246
21.

Role of global regulator Rma for multidrug efflux-mediated fluoroquinolone resistance in Salmonella.

Feuerriegel S, Heisig P.

Microb Drug Resist. 2008 Dec;14(4):259-63. doi: 10.1089/mdr.2008.0846.

PMID:
19018673
22.

Molecular characterisation of linezolid resistance in two vancomycin-resistant (VanB) Enterococcus faecium isolates using Pyrosequencing.

Saager B, Rohde H, Timmerbeil BS, Franke G, Pothmann W, Dahlke J, Scherpe S, Sobottka I, Heisig P, Horstkotte MA.

Eur J Clin Microbiol Infect Dis. 2008 Sep;27(9):873-8. doi: 10.1007/s10096-008-0514-6. Epub 2008 Apr 18.

PMID:
18421487
23.

Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain.

Hentschke M, Saager B, Horstkotte MA, Scherpe S, Wolters M, Kabisch H, Grosse R, Heisig P, Aepfelbacher M, Rohde H.

Infection. 2008 Feb;36(1):85-7. doi: 10.1007/s15010-007-7220-7. Epub 2007 Dec 28. No abstract available.

PMID:
18165857
24.

[Actions and resistance mechanisms of beta-lactam antibiotics. Penicillin-binding proteins, beta-3-lactamases and signal proteins].

Heisig P.

Pharm Unserer Zeit. 2006;35(5):400-8. Review. German. No abstract available.

PMID:
17009783
25.

Role of novel gyrA mutations in the suppression of the fluoroquinolone resistance genotype of vaccine strain Salmonella Typhimurium vacT (gyrA D87G).

Preisler A, Mraheil MA, Heisig P.

J Antimicrob Chemother. 2006 Mar;57(3):430-6. Epub 2006 Jan 23.

PMID:
16431864
26.

A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.

Gruger T, Nitiss JL, Maxwell A, Zechiedrich EL, Heisig P, Seeber S, Pommier Y, Strumberg D.

Antimicrob Agents Chemother. 2004 Dec;48(12):4495-504.

27.

[What's new in ketolides and oxazolidinones? Actions and resistance mechanisms].

Heisig P.

Pharm Unserer Zeit. 2004;33(1):10-9. Review. German. No abstract available.

PMID:
14968708
28.

Clinically significant borderline resistance of sequential clinical isolates of Klebsiella pneumoniae.

Wagenlehner FM, Heisig P, Irtenkauf C, Notka F, Decker J, Lehn N, Linde H.

Int J Antimicrob Agents. 2003 Oct;22(4):367-73.

PMID:
14522099
29.

Synthesis and antimicrobial activity of tetrodecamycin partial structures.

Paintner FF, Allmendinger L, Bauschke G, Berns C, Heisig P.

Bioorg Med Chem. 2003 Jul 3;11(13):2823-33.

PMID:
12788355
30.

Topoisomerase IV mutations in quinolone-resistant salmonellae selected in vitro.

Hansen H, Heisig P.

Microb Drug Resist. 2003 Spring;9(1):25-32.

PMID:
12705680
31.

Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae.

Linde HJ, Notka F, Irtenkauf C, Decker J, Wild J, Niller HH, Heisig P, Lehn N.

J Antimicrob Chemother. 2002 Apr;49(4):625-30.

PMID:
11909836
32.

[Bacterial antibiotic resistance from ion channels].

Heisig P.

Med Monatsschr Pharm. 2002 Jan;25(1):2-3. German. No abstract available.

PMID:
11826663
33.

[Action and reaction. Actions and resistance mechanisms of quinolone].

Heisig P, Wiedemann B.

Pharm Unserer Zeit. 2001;30(5):382-93. Review. German. No abstract available.

PMID:
11575174
34.

In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.

Kraiczy P, Weigand J, Wichelhaus TA, Heisig P, Backes H, Schäfer V, Acker G, Brade V, Hunfeld KP.

Antimicrob Agents Chemother. 2001 Sep;45(9):2486-94.

35.

Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.

Ackermann G, Tang YJ, Kueper R, Heisig P, Rodloff AC, Silva J Jr, Cohen SH.

Antimicrob Agents Chemother. 2001 Aug;45(8):2348-53.

36.

In vitro activity of sitafloxacin against Clostridium difficile.

Ackermann G, Tang YJ, Rodloff AC, Silva J Jr, Cohen SH, Heisig P.

J Antimicrob Chemother. 2001 May;47(5):722-4. No abstract available.

PMID:
11328798
37.
38.

In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Boos M, Mayer S, Fischer A, Köhrer K, Scheuring S, Heisig P, Verhoef J, Fluit AC, Schmitz FJ.

Antimicrob Agents Chemother. 2001 Mar;45(3):938-42.

39.
40.

["Medical micro biology for pharmacists" or pharmaceutical micro biology].

Heisig P, Wiedemann B.

Med Monatsschr Pharm. 2000 Jun;23(6):173-5. German. No abstract available.

PMID:
10885256
41.

In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR.

Linde HJ, Notka F, Metz M, Kochanowski B, Heisig P, Lehn N.

Antimicrob Agents Chemother. 2000 Jul;44(7):1865-8.

42.

Beta-lactamase expression in Yersinia enterocolitica biovars 1A, 1B, and 3.

Stock I, Heisig P, Wiedemann B.

J Med Microbiol. 2000 May;49(5):403-8.

PMID:
10798551
44.

Expression of beta-lactamases in Yersinia enterocolitica strains of biovars 2, 4 and 5.

Stock I, Heisig P, Wiedemann B.

J Med Microbiol. 1999 Nov;48(11):1023-7.

PMID:
10535647
45.

Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.

Brisse S, Fluit AC, Wagner U, Heisig P, Milatovic D, Verhoef J, Scheuring S, Köhrer K, Schmitz FJ.

Antimicrob Agents Chemother. 1999 Oct;43(10):2513-6.

46.

[DNA as a drug].

Heisig P.

Pharm Unserer Zeit. 1999 May;28(3):130-7. Review. German. No abstract available.

PMID:
10399463
47.

The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.

Schedletzky H, Wiedemann B, Heisig P.

J Antimicrob Chemother. 1999 May;43 Suppl B:31-7.

PMID:
10382873
48.

Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Bagel S, Hüllen V, Wiedemann B, Heisig P.

Antimicrob Agents Chemother. 1999 Apr;43(4):868-75.

49.

[New 4-quinolone derivatives in review].

Holzgrabe U, Heisig P.

Pharm Unserer Zeit. 1999 Jan;28(1):30-5. Review. German. No abstract available.

PMID:
10078027

Supplemental Content

Loading ...
Support Center